Wang Huan, Bender Aaron, Wang Peng, Karakose Esra, Inabnet William B, Libutti Steven K, Arnold Andrew, Lambertini Luca, Stang Micheal, Chen Herbert, Kasai Yumi, Mahajan Milind, Kinoshita Yayoi, Fernandez-Ranvier Gustavo, Becker Thomas C, Takane Karen K, Walker Laura A, Saul Shira, Chen Rong, Scott Donald K, Ferrer Jorge, Antipin Yevgeniy, Donovan Michael, Uzilov Andrew V, Reva Boris, Schadt Eric E, Losic Bojan, Argmann Carmen, Stewart Andrew F
The Department of Genetics and Genomic Sciences and The Icahn Institute for Genomics and Multiscale Biology, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
The Graduate School, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Nat Commun. 2017 Oct 3;8(1):767. doi: 10.1038/s41467-017-00992-9.
Although diabetes results in part from a deficiency of normal pancreatic beta cells, inducing human beta cells to regenerate is difficult. Reasoning that insulinomas hold the "genomic recipe" for beta cell expansion, we surveyed 38 human insulinomas to obtain insights into therapeutic pathways for beta cell regeneration. An integrative analysis of whole-exome and RNA-sequencing data was employed to extensively characterize the genomic and molecular landscape of insulinomas relative to normal beta cells. Here, we show at the pathway level that the majority of the insulinomas display mutations, copy number variants and/or dysregulation of epigenetic modifying genes, most prominently in the polycomb and trithorax families. Importantly, these processes are coupled to co-expression network modules associated with cell proliferation, revealing candidates for inducing beta cell regeneration. Validation of key computational predictions supports the concept that understanding the molecular complexity of insulinoma may be a valuable approach to diabetes drug discovery.Diabetes results in part from a deficiency of functional pancreatic beta cells. Here, the authors study the genomic and epigenetic landscapes of human insulinomas to gain insight into possible pathways for therapeutic beta cell regeneration, highlighting epigenetic genes and pathways.
尽管糖尿病部分是由于正常胰腺β细胞缺乏所致,但诱导人类β细胞再生却很困难。鉴于胰岛素瘤拥有β细胞扩张的“基因组配方”,我们研究了38例人类胰岛素瘤,以深入了解β细胞再生的治疗途径。采用全外显子组和RNA测序数据的综合分析,广泛描述胰岛素瘤相对于正常β细胞的基因组和分子特征。在这里,我们在通路水平上表明,大多数胰岛素瘤表现出突变、拷贝数变异和/或表观遗传修饰基因的失调,最显著的是在多梳家族和三胸家族中。重要的是,这些过程与细胞增殖相关的共表达网络模块相关联,揭示了诱导β细胞再生的候选基因。对关键计算预测的验证支持了这样一种概念,即了解胰岛素瘤的分子复杂性可能是糖尿病药物发现的一种有价值的方法。糖尿病部分是由于功能性胰腺β细胞缺乏所致。在这里,作者研究了人类胰岛素瘤的基因组和表观遗传特征,以深入了解治疗性β细胞再生的可能途径,突出了表观遗传基因和途径。